Proteome Sciences Outlicenses Proteins for Lung Cancer Dx; Increasing TMT to 12- and 18-Plex | GenomeWeb
NEW YORK (GenomeWeb News) - UK cancer detection firm Oncimmune will develop a diagnostic test for lung cancer using Proteome Sciences’ patents covering the Annexin I and Annexin 2 proteins under a non-exclusive licensing agreement announced by the two firms this week.
 
A test is expected to hit the market during the first half of the year, Proteome Sciences said in a statement. It will receive royalty payments from product sales under the agreement.
 
Further terms of the deal were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.